Neuroblastoma

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1430-1437

  Castleberry, R P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biology; Neuroblastoma; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; DEFEROXAMINE; GANGLIOSIDE ANTIBODY; GYRASE INHIBITOR; RETINOID;

CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; GENE THERAPY; HUMAN; INFANT; MULTIMODALITY CANCER THERAPY; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0030827080     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00308-0     Document Type: Article

References (111)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In Pizzo PA, Poplack DG, eds Principles and Practice of Pediatric Oncology. Philadelphia, J. B. Lippincott Co., 1997, 761-797.
2. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Cancer 1996, 75, 2186-2195.
3. Miller RW, Young Jr JL, Novakovic B. Childhood cancer. Cancer 1995, 75, 395-405.
4. Allen RW, Ogden B, Bentley FL, Jung AL. Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate. Journal of the American Medical Association 1996, 244, 1464-1465.
5. Kinney H, Faix R, Brazy J. The fetal alcohol syndrome and neuroblastoma. Pediatrics 1996, 66, 130-132.
6. Schwartzbaum JA. Influence of the mother's prenatal drug consumption on risk of neuroblastoma in the child. American Journal of Epidemiology 1996, 135, 1358-1367.
7. Seeler RA, Israel JN, Royal JE, Kaye CI, Rao S, Abulaban M. Ganglioneuroblastoma and fetal hydantoin-alcohol syndromes. Pediatrics 1979, 63, 524-527.
8. Spitz MR, Johnson CC. Neuroblastoma and paternal occupation. A case-control analysis. American Journal of Epidemiology 1985, 121, 924-929.
9. Wilkins JRI, Hundley VD. Paternal occupational exposure to electromagnetic fields and neuroblastoma in offspring. American Journal of Epidemiology 1990, 131, 995-1008.
10. Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proceedings of the National Academy of Sciences, U.S.A. 1990, 87, 5454-5458.
11. Klein R, Jing S, Nanduri V, O'Rourke E, Barbacid M. The TRK proto-oncogene encodes a receptor for nerve growth factor. Cell 1991, 65, 189-197.
12. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. The New England Journal of Medicine 1993, 328, 847-854.
13. Borrello MG, Bongarzone I, Pierotti MA, et al. TRK and RET protooncogene expression in human neuroblastoma specimens: high-frequency of TRK expression in non-advanced stages. International Journal of Cancer 1993, 54, 540-545.
14. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Research 1993, 53, 2044-2050.
15. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Research 1992, 52, 1364-1368.
16. Suzuki T, Bogenmann E, Shimada H, Strain D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. Journal of the National Cancer Institute 1993, 85, 377-384.
17. Beckwith J, Perrin E. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. American Journal of Pathology 1963, 43, 1089-1104.
18. Ikeda Y, Lister J, Bouton JM, Buyukpamukcu M. Congenital neuroblastoma, neuroblastoma in situ and the normal fetal development of the adrenal. Journal of Pediatric Surgery 1981, 16, 636-644.
19. Haase D, Ablin AR, Miller C, Zoger S, Matthay KK. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988, 62, 818-825.
20. Bessho F, Hashizume K, Nakajo T, Kamoshita S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. Journal of Pediatrics 1991, 119, 237-241.
21. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996, 348, 1682.
22. Kellie SJ, Hayes FA, Bowman L, et al. Primary extracranial neuroblastoma with central nervous system metastases. Characterization by clinicopathologic findings and neuroimaging. Cancer 1991, 68, 1999-2006.
23. Shaw PJ, Eden T. Neuroblastoma with intracranial involvement: an ENSG study. Medical and Pediatric Oncology 1992, 20, 149-155.
24. Watts RG, Mroczek-Musulman E. Pulmonary interstitial disease mimicking idiopathic pneumonia syndrome as the initial site of relapse of neuroblastoma following autologous bone marrow transplantation: a case report. American Journal of Hematology 1996, 53, 137-140.
25. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. Journal of Clinical Oncology 1988, 6, 1874-1881.
26. Brodeur GM, Pritchard J, Berthold F, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology 1993, 11, 1466-1477.
27. Castleberry RP, Pritchard J, Ambros P, et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Europ. J Cancer 1996.
28. American Joint Committee on Cancer. Neuroblastoma. Manual for Staging of Cancer. Philadelphia, J. B. Lippincott, Co., 1983, 237-239.
29. Evans AE, D'Angio GJ, Randolph JA. A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 1971, 27, 374-378.
30. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery - a Pediatric Oncology Group Study. Journal of Clinical Oncology 1988, 6, 1271-1279.
31. Nitschke R, Smith EI, Altshuler G, et al. Treatment of grossly unresectable localized neuroblastoma. A Pediatric Oncology Group study. Journal of Clinical Oncology 1991, 9, 1181-1188.
32. De Bernardi B, Rogers D, Carli M, et al. Localized neuroblastoma. Surgical and pathological staging. Cancer 1987, 60, 1066-1072.
33. Nakagawara A, Morita K, Okabe I, et al. Proposal and assessment of Japanese Tumor Node Metastasis postsurgical histopathological staging system for neuroblastoma based on an analysis of 495 cases. Japanese Journal of Clinical Oncology 1990, 21, 1-7.
34. Sawaguchi S, Suganuma Y, Watanabe I, et al. Studies of the biological and clinical characteristics of neuroblastoma. III. Evaluation of the survival rate in relation to 17 factors. Nippon Shoni Geka Gakkai Zasshi 1980, 16, 51-66.
35. Castleberry RP, Shuster JJ, Altshuler G, et al. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group Study. Journal of Clinical Oncology 1992, 10, 1299-1304.
36. Hayes FA, Green AA, Hustu HO, Kumar M. Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases. Journal of Pediatrics 1983, 102, 59-62.
37. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. Journal of Clinical Oncology 1989, 7, 236-244.
38. Ninane J, Pritchard J, Jones PHM, Malpas JS. Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement. Archives of Diseases in Childhood 1982, 57, 438-442.
39. D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet 1971, 1, 1046-1049.
40. Evans AE, Chatten J, D'Angiom GJ, Gerson JM, Robinson J, Schnaufer L. A review of 17 IV-S neuroblastoma patients at the children's hospital of Philadelphia. Cancer 1980, 45, 833-839.
41. Evans AE, Baum E, Chard R. Do infants with stage IV-S neuroblastoma need treatment? Archives of Diseases in Childhood 1981, 56, 271-274.
42. Castleberry RP, Shuster JJ, Smith EI. The POG experience with the International Staging System. Journal of Clinical Oncology 1994, 12, 2378-2381.
43. Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the International Staging systems. Journal of Pediatric Surgery 1995, 30, 289-294.
44. Carlsen NLT, Christensen IJ, Schroeder H, et al. Prognostic factors in neuroblastomas treated in Denmark from 1943 to 1980. A statistical estimate of prognosis based on 253 cases. Cancer 1986, 58, 2726-2735.
45. Coldman AJ, Fryer CJH, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 1980, 46, 1896-1901.
46. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann H-WL. Prognostic factors in neuroblastoma. Cancer 1987, 59, 1853-1859.
47. Grosfeld JL, Schatzlein M, Ballantine TVN, Weetman RM, Baehner RL. Metastatic neuroblastoma: factors influencing survival. Journal of Pediatric Surgery 1978, 13, 59-65.
48. Jaffe N. Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treatment Reviews 1976, 3, 61-82.
49. Jereb B, Bretsky SS, Vogel R, Helson L. Age and prognosis in neuroblastoma. Review of 112 patients younger than 2 years. American Journal of Pediatric Hematology/Oncology 1984, 6, 233-243.
50. Berthold F, Trechow R, Utsch S, Zieschang J. Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. American Journal of Pediatric Hematology/Oncology 1992, 14, 207-215.
51. Hann HWL, Evans AE, Siegel SE, et al. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma. The Children's Cancer Study Group Experience. Cancer Research 1985, 45, 2843-2848.
52. Marangos P. Clinical studies with neuron specific enolase. Progress in Clinical and Biological Research 1985, 175, 285-294.
53. Shuster JJ, McWilliams NB, Castleberry R, et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. American Journal of Clinical Oncology 1992, 15, 295-303.
54. Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Research 1991, 51, 1426-1433.
55. Tsuchida Y, Honna T, Iwanaka T, et al. Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors. Journal of Pediatric Surgery 1987, 22, 419-124.
56. Shimada H, Chatten J, Newton Jr WA. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. Journal of the National Cancer Institute 1984, 73, 405-413.
57. Joshi V, Cantor A, Altshuer G, et al. Age-linked prognostic categorisation base on a new histologic grading of neuroblastoma. Cancer 1992, 69, 2197.
58. Roald B, Ambros I, Dehner LP, Hata J-I, Joshi V. H S. A proposed international neuroblastoma pathology classification. Med Ped Oncol 1996, 27, 225.
59. Brodeur GM, Seeger RC, Sather H, et al. Clinical implications of oncogene activation in human neuroblastomas. Cancer 1986, 58, 541-545.
60. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224, 1121-1124.
61. Caron H, Peter M, van Sluis P, et al. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Human Molecular Genetics 1995, 4, 535-539.
62. Fong CT, Dracopoli NC, White PS. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proceedings of the National Academy of Sciences, U.S.A. 1989, 86, 3753-3757.
63. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. New England Journal of Medicine 1984, 311, 231-235.
64. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Brodeur GM. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma. A Pediatric Oncology Group study. Journal of Clinical Oncology 1991, 9, 581-591.
65. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New England Journal of Medicine 1985, 313, 1111-1116.
66. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Research 1981, 41, 4678-4686.
67. Cohn SL, Brodeur GM, Holbrook T, et al. N-myc gene amplification in localized neuroblastoma. A Pediatric Oncology Group Study. Cancer Research 1995, 55, 721-726.
68. Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian experience with 295 children. Journal of Clinical Oncology 1997, 15, 85-93.
69. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Medical and Pediatric Oncology 1995, 24, 215-221.
70. Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amler LC, Berthold F. Neuroblastoma consensus deletion maps to 1p36.1-2. Genes, Chromosomes & Cancer 1989, 1, 159-166.
71. Chan HSL, Haddad G, Thorner PS. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New England Journal of Medicine 1991, 325, 1608-1614.
72. Norris MD, Bordow SB, Marshall GM, Haber PS, Haber M. Association between high levels of expression of the multidrug resistance-associated protein (MRP) gene and poor outcome in primary human neuroblastoma. New England Journal of Medicine 1996, 334, (in press).
73. Leone A, Seeger RC, Hong CM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993, 8, 855-865.
74. Favrot MC, Combaret V, Lasset C. CD44 - a new prognostic marker for neuroblastoma. New England Journal of Medicine 1993, 329, 1965.
75. Norris MD, Bordow SB, Madafiglio J, et al. Down-regulation of the N-myc oncogene modulates expression of MRP gene and response to cytotoxic drugs. American Association of Cancer Research 38. San Diego, CA, 1997, 440.
76. Brodeur GM, Azar C, Brother M, et al. Neuroblastoma: effect of genetic factors on prognosis and treatment. Cancer 1992, 70, 1685-1694.
77. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. European Journal of Cancer 1995, 31A, 505-510.
78. Evans AE, Silber JH, Shpilsky A, GJ D. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. Journal Clinical Oncology 1996, 14, 2504-2510.
79. Smith EI, Haase GM, Seeger RC, Brodeur GM. A surgical perspective on the current staging in neuroblastoma - the international neuroblastoma staging system proposal. Journal of Pediatric Surgery 1989, 24, 386-390.
80. Castleberry RP, Kun L, Shuster JJ, et al. Radiotherapy improves the outlook for children older than one year with POG stage C neuroblastoma. Journal of Clinical Oncology 1991, 9, 789-795.
81. Strother D, Cantor A, Halperin E, et al. Treatment of Pediatric Oncology Group stage C neuroblastoma: a preliminary POG report [Abstract]. Proceedings of the American Society of Clinical Oncology 1993, 12, 1422.
82. McWilliams NB. Neuroblastoma in infancy. In Pochedly C, ed. Neuroblastoma: Tumor Biology and Therapy. Boca Raton, CRC Press, 1990, 229-243.
83. Stephenson SR, Cook BA, Mease AD, Ruymann FB. The prognostic significance of age and pattern of metastases in stage IV-S neuroblastoma. Cancer 1986, 58, 372.
84. Strother D, Shuster JJ, McWilliams N, et al. Results of Pediatric Oncology Group protocol 8104 for infants with stages D and DS neuroblastoma. Journal of Pediatric Hematology/Oncology 1995, 17, 254-259.
85. Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favorable neuroblastoma is independent of the degree of initial tumor resection results from the Pediatric Oncology Group. European Journal of Cancer 1997, (in press).
86. Seeger RC, Reynolds CP. Neuroblastomas. In Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Cambridge, Blackwell Scientific, 1994, 814-826.
87. Graham-Pole J. Autologous marrow transplants in pediatric tumors. In Champlin RE, Gale RP, eds. New Strategies in Bone Marrow Transplantation. New York, Wiley-Liss, Inc., 1991, 413-422.
88. Seeger RC, Matthay KK, Villablanca JG, et al. Intensive chemoradiotherapy and autologous bone marrow transplantation (ABMT) for high risk neuroblastoma [Abstract]. Proceedings of the American Society of Clinical Oncology 1991, 10, 310.
89. Philip T, Zucker JM, Bernard JL, et al. Bone marrow transplantation in an unselected group of 65 patients with stage IV neuroblastoma. In Dicke KA, Spitzer G, Jagannath S, eds. Autologous Bone Marrow Transplantation III. Houston, University of Texas, 1987, 407.
90. Graham-Pole J, Casper J, Elfenbein G, et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. Journal of Clinical Oncology 1991, 9, 152-158.
91. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma; a report of two concurrent Children's Cancer Group studies. Journal of Clinical Oncology 1996, 14, 2417-2426.
92. Garaventa A, Rondelli R, Lanino E, et al. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Bone Marrow Transplantation 1996, 18, 125-130.
93. Zucker JM, Bernard JL, Philip T, Gentet JC, Michon J, Bouffet E. High dose chemotherapy with BMT as consolidation treatment in neuroblastoma - the LMCE 1 unselected group of patients revisited with a median follow up of 55 months after BMT [Abstract]. Proceedings of the American Society of Clinical Oncology 1990, 9, 294.
94. Pritchard J, McElwain TJ, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. British Journal of Cancer 1982, 45, 86-94.
95. Pinkerton CR, Pritchard J, DeKraker J, et al. ENSG 1 - Randomised study of high dose melphalan in neuroblastoma. In Dicke KA, Spitzer G, Jagonnoth S, eds. Autologous Bone Marrow Transplantation. University of Texas Press, 1987, 401.
96. Kletzel M, Longino R, Danner K, Olszewski M. T M. Peripheral blood stem cell rescue in children with advanced stage neuroblastoma. Progress in Clinical and Biological Research 1994, 389, 513-519.
97. Hoefnagel CA, De Kraker J, Valder Olmos RA, Voute PA. [131I]MIBG as first line treatment in advance neuroblastoma. Quarterly Journal of Nuclear Medicine 1995, 39, 61-64.
98. Matthay KK, Huberty JP, Hattner RS, et al. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. Journal of Nuclear Biology and Medicine 1991, 35, 244-247.
99. van Hasselt EF, Heif HA, De Kraker J, Vos A, Voute PA. Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advance neuroblastoma. European Journal of Pediatric Surgery 1996, 6, 155-158.
100. Voute PA, Hoefnagel CA, de Kraker J, Olmos RV, Bakker DJ, van de Kleij AJ. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma, future prospects of zetotherapy. Progress in Clinical and Biological Research 1991, 366, 439-445.
101. Troncone L, Rufini V, Luzi S, Mastrangelo R. R R. The treatment of neuroblastoma with [131I]MIBG at diagnosis. Quarterly Journal of Nuclear Medicine 1995, 39, 65-68.
102. Berthold F, Hunneman DH, Kaser H, et al. Neuroblastoma screening: arguments from retrospective analysis of three German neuroblastoma trials. American Journal of Pediatric Hematology/Oncology 1991, 13, 8-13.
103. Chauvin F, Mathieu P, Frappaz D, et al. Screening for neuroblastoma in France: methodological aspects and preliminary observations. Medical and Pediatric Oncology 1997, 28, 81-91.
104. Villablanca JG, Khan AA, Avramis VI, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. Journal of Clinical Oncology 1995, 13, 894-901.
105. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. European Journal of Cancer 1995, 31A, 261-267.
106. Yu AL, Gillies SD, Reisfeld RA. Phase I clinical trial of CH14.18 in patients with refractory neuroblastoma [Abstract]. Proceedings of the American Society of Clinical Oncology 1991, 10, 318.
107. Gaze MN, Wheldon TE, O'Donoghue JA, et al. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. European Journal of Cancer 1995, 31A, 252-256.
108. Pardo N, Marti F, Fraga G, et al. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Medical and Pediatric Oncology 1996, 27.
109. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Research 1990, 50, 4929-4931.
110. Liu L, Wang J. Biochemistry of DNA topoisomerases and their poisons. New York, Oxford Press, 1991.
111. Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. American Journal of Pediatric Hematology/Oncology 1992, 14, 111-116.